Improving Bone Health Among RA Patients on Chronic Glucocorticoids
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Adverse Effect of Glucocorticoids and Synthetic Analogues
- Sponsor
- University of Alabama at Birmingham
- Enrollment
- 4659
- Locations
- 1
- Primary Endpoint
- Number of participants receiving Anti-osteoporosis Treatment
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
This quality improvement project is aimed at improving health care by identifying low cost strategies to get Rheumatoid Arthritis (RA) patients to more effectively communicate with their physicians about osteoporosis prevention and treatment (improving doctor-patient communication). The investigators will implement a direct to patient intervention to the population of interest (patients on chronic glucocorticoids) via story-telling, using an Internet based video. The target audience is people on chronic glucocorticoids not already receiving bones-specific osteoporosis medications to determine differences in post-intervention rates of osteoporosis care, and the rates of prescription anti-osteoporosis therapies.
Investigators
Kenneth Saag, MD, MSc
Jane Knight Lowe Professor of Medicine
University of Alabama at Birmingham
Eligibility Criteria
Inclusion Criteria
- •Greater than or equal to 5 milligrams of prednisone or glucocorticoid dose equivalent for greater than or equal to 90 days within the previous 12 months
- •Medco member for entire study period
- •Refill steroid prescription online
Exclusion Criteria
- •anti-osteoporosis medication in previous 12 months
Outcomes
Primary Outcomes
Number of participants receiving Anti-osteoporosis Treatment
Time Frame: within 3 - 12 months of exposure to video
Includes bisphosphonates, PTH, SERM, Calcitonin
Secondary Outcomes
- Calcium and Vitamin D use(within 3 - 12 months of exposure to video)
- Patient-Physician Communication(within 3 - 12 months of exposure to video)